BriaCell Announces Proposed Effective Date of Share Consolidation
BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT) has announced a share consolidation plan to maintain Nasdaq listing compliance. The consolidation will be executed on a 15:1 basis, where every fifteen pre-consolidation common shares will be converted into one post-consolidation share.
The consolidation is scheduled to take effect on January 24, 2025, with trading of post-consolidation shares beginning on January 29, 2025 on both TSX and Nasdaq, subject to final exchange approvals. The company will maintain its trading symbols 'BCT' on TSX and 'BCTX' on Nasdaq, but under a new CUSIP number: 107930208.
No fractional shares will be issued, and any resulting fractional shares will be cancelled without compensation. The consolidation will proportionally adjust all convertible securities' exercise prices and share quantities. Registered shareholders will receive instructions via letter from Computershare Investor Services Inc. for exchanging their shares.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT) ha annunciato un piano di consolidamento delle azioni per mantenere la conformità alla lista Nasdaq. Il consolidamento sarà eseguito su base 15:1, dove ogni quindici azioni comuni pre-consolidamento saranno convertite in un'azione post-consolidamento.
Il consolidamento è previsto per il 24 gennaio 2025, con l'inizio delle negoziazioni delle azioni post-consolidamento il 29 gennaio 2025 su TSX e Nasdaq, soggetto all'approvazione finale degli scambi. L'azienda manterrà i suoi simboli di negoziazione 'BCT' su TSX e 'BCTX' su Nasdaq, ma sotto un nuovo numero CUSIP: 107930208.
Non verranno emesse azioni frazionarie, e eventuali azioni frazionarie risultanti saranno annullate senza compenso. Il consolidamento regolerà proporzionalmente i prezzi di esercizio e le quantità delle tutte le securities convertibili. Gli azionisti registrati riceveranno istruzioni tramite lettera da Computershare Investor Services Inc. per il cambio delle loro azioni.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT) ha anunciado un plan de consolidación de acciones para mantener el cumplimiento de la lista del Nasdaq. La consolidación se llevará a cabo en una base de 15:1, donde cada quince acciones comunes antes de la consolidación se convertirán en una acción posterior a la consolidación.
La consolidación está programada para entrar en efecto el 24 de enero de 2025, con el inicio de la negociación de las acciones posteriores a la consolidación el 29 de enero de 2025 tanto en TSX como en Nasdaq, sujeto a la aprobación final de los intercambios. La compañía mantendrá sus símbolos de negociación 'BCT' en TSX y 'BCTX' en Nasdaq, pero bajo un nuevo número CUSIP: 107930208.
No se emitirán acciones fraccionarias, y cualquier acción fraccionaria resultante será cancelada sin compensación. La consolidación ajustará proporcionalmente los precios de ejercicio y las cantidades de todas las securities convertibles. Los accionistas registrados recibirán instrucciones por carta de Computershare Investor Services Inc. para el intercambio de sus acciones.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT)는 나스닥 상장 준수를 유지하기 위한 주식 통합 계획을 발표했습니다. 통합은 15:1 비율로 시행되며, 통합 전 15주가 통합 후 1주로 변환됩니다.
통합은 2025년 1월 24일에 발효될 예정이며, 통합 후 주식의 거래는 2025년 1월 29일에 TSX 및 나스닥에서 시작됩니다. 이는 최종 거래소 승인에 따라 진행됩니다. 회사는 TSX에서 'BCT', 나스닥에서 'BCTX'라는 거래 기호를 유지하겠지만 새로운 CUSIP 번호: 107930208로 변경됩니다.
부분 주식은 발행되지 않으며, 생성된 부분 주식은 보상 없이 취소됩니다. 통합은 모든 전환 가능한 증권의 행사가격 및 주식 수를 비례적으로 조정합니다. 등록된 주주는 Computershare Investor Services Inc.로부터 주식 교환을 위한 안내문을 받을 것입니다.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT) a annoncé un plan de consolidation des actions pour maintenir la conformité à la cotation Nasdaq. La consolidation sera réalisée sur une base de 15:1, où chaque quinze actions ordinaires avant consolidation seront converties en une action après consolidation.
La consolidation devrait entrer en vigueur le 24 janvier 2025, avec le début des transactions des actions post-consolidation le 29 janvier 2025 sur le TSX et le Nasdaq, sous réserve des approbations finales des échanges. La société conservera ses symboles de négociation 'BCT' sur le TSX et 'BCTX' sur le Nasdaq, mais sous un nouveau numéro CUSIP : 107930208.
Aucune action fractionnée ne sera émise, et toutes les actions fractionnées résultantes seront annulées sans compensation. La consolidation ajustera proportionnellement les prix d'exercice et les quantités de tous les titres convertibles. Les actionnaires inscrits recevront des instructions par courrier de Computershare Investor Services Inc. pour échanger leurs actions.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT) hat einen Plan zur Konsolidierung von Aktien angekündigt, um die Einhaltung der Nasdaq-Listung zu gewährleisten. Die Konsolidierung wird im Verhältnis 15:1 durchgeführt, wobei jede fünfzehnte vor der Konsolidierung ausgegebene Stammaktie in eine nach der Konsolidierung ausgegebene Aktie umgewandelt wird.
Die Konsolidierung wird am 24. Januar 2025 wirksam, der Handel mit den nach der Konsolidierung ausgegebenen Aktien beginnt am 29. Januar 2025 sowohl an der TSX als auch an der Nasdaq, vorbehaltlich der endgültigen Genehmigungen der Börsen. Das Unternehmen wird seine Handelssymbole 'BCT' an der TSX und 'BCTX' an der Nasdaq beibehalten, jedoch unter einer neuen CUSIP-Nummer: 107930208.
Es werden keine Bruchaktien ausgegeben, und alle entstehenden Bruchaktien werden ohne Entschädigung storniert. Die Konsolidierung wird die Ausübungspreise und Anzahl der gesamten wandlungsfähigen Wertpapiere proportional anpassen. Eingetragene Aktionäre erhalten Anweisungen per Brief von Computershare Investor Services Inc. zur Umtauschung ihrer Aktien.
- None.
- Share consolidation (reverse split) required to maintain Nasdaq listing compliance, indicating potential listing issues
- Fractional shares will be cancelled without compensation to shareholders
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every fifteen (15) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”).
The Consolidation is subject to approval by the Toronto Stock Exchange (the “TSX”) and is expected to become effective on January 24, 2025 (the “Effective Date”), with the post-Consolidation Common Shares commencing trading on the TSX and the Nasdaq at market open on January 29, 2025, subject to final confirmation from the TSX and the Nasdaq. No fractional Common Shares will be issued in connection with the Consolidation. Any fractional Common Shares arising from the Consolidation will be deemed to have been tendered by its registered owner to the Company for cancellation for no consideration. The exercise or conversion price and/or the number of Common Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted in connection with the Consolidation.
It is anticipated that upon completion of the Consolidation, the post-Consolidation Common Shares will continue to trade on the TSX under the symbol “BCT” and on the Nasdaq under the symbol “BCTX”, under a new CUSIP number: 107930208.
Shareholders of record as of the Effective Date will receive a letter of transmittal from Computershare Investor Services Inc., the transfer agent for the Common Shares, providing instructions for the exchange of their Common Shares as soon as practicable following the Effective Date.
Registered shareholders may also obtain a copy of the letter of transmittal by accessing the Company’s SEDAR+ profile at www.sedarplus.ca. Until surrendered, each share certificate or direct registration system statement representing pre-Consolidation Common Shares will represent the number of whole post-Consolidation Common Shares to which the holder is entitled as a result of the Consolidation. No action is required by beneficial holders to receive post-Consolidation Common Shares in connection with the Consolidation. Beneficial holders who hold their Common Shares through intermediaries (e.g., a broker, bank, trust company investment dealer or other financial institution) and who have questions regarding how the Consolidation will be processed should contact their intermediaries with respect to the Consolidation.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
CORE IR
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
FAQ
What is the ratio of BriaCell's (BCTXF) share consolidation announced for January 2025?
When will BCTXF's share consolidation take effect and begin trading?
What happens to fractional shares in BCTXF's January 2025 consolidation?
How will BCTXF's share consolidation affect existing convertible securities?
Why is BriaCell (BCTXF) implementing a share consolidation in January 2025?
